Clinical Trial Update: FAIR-PARK II

The FAIR-PARK II trial (Conservative Iron Chelation as a Disease-Modifying Strategy in Parkinson's Disease, PD) has held site initiation visits at all participating sites in France (sponsor country). The first patient was enrolled in February 2016. 

Following regulatory and ethical approval in the additional participating countries (UK, Germany, Austria, Spain, Portugal, the Netherlands, Czech Republic), site initiation visits are expected to be held at all sites and initiation of patient recruitment in September 2016 in these countries.

Funded by Horizon 2020, FAIR-PARK II is coordinated by France (CHRU Lille, Prof. Devos); ECRIN provides operational services to the sponsor for the conduct of the multinational trial (regulatory and ethical submissions, monitoring and local pharmacovigilance) upon delegation.

FAIR-PARK II has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 633190.